Mesoblast believes these additional data will provide a link between the RYONCIL product that
was used in the Phase 3 trial MSB-GVHD001 for the pediatric indication to the RYONCIL product
which will be used in a future trial for the adult indication.
Ok - sorry - not following as closely as the 40 hour a week emergency doctor- is this a stitch up?
The adult potency assay is based on the kid assay that met its endpoint/ here is the data
no wonder he is chirpy
Reg
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-342
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.005(0.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 98.5¢ | 98.5¢ | 96.0¢ | $2.168M | 2.226M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16000 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.0¢ | 86854 | 7 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |